[Show abstract][Hide abstract] ABSTRACT: The objective of this systematic review was to assess the evidence from rigorous clinical trials evaluating the efficacy of mixed herbal medicine formulations used in traditional Oriental medicines for the treatment of obesity and to describe the safety and types of adverse events reported in such trials. To accomplish this, 14 databases were searched from inception to July 31, 2009. The search terms used were "obesity" or "obese" and "herb," "herbal," or "herbal medicine" without language restriction. All randomized clinical trials using mixed herbal medicines on obese or overweight subjects were considered for inclusion. Of the publications in the identified databases, 1144 results were searched and reviewed, and in total 12 studies were included. Their methodological quality was assessed using the Jadad score. The results of our review provide evidence suggesting that mixed Oriental herbal medicines may be safe and effective for the treatment of obesity when compared with conventional medicine, placebos, or lifestyle control. Many trials also reported improved concomitant conditions including impaired glucose tolerance, hypertension, and inflammation. Small numbers of adverse events were reported, but most were mild or not related to the intervention in itself. No significant mortality was observed in any of the trials. However, the evidence provided by the trials reviewed is not fully convincing because of their poor methodological quality. Therefore, more research and well-designed clinical trials are necessary to address these issues, as well as to assess the safety of mixed Oriental herbal medicines used to treat obesity.
Journal of medicinal food 05/2012; 15(7):589-97. · 1.39 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Bangpungtongseong-san (Bofutsushosan, BTS) and Bangkihwangki-tang (Boiogito, BOT) are widely prescribed Korean, Japanese and Chinese traditional herbal medicines used to clinically prevent or improve obesity. In this study, we investigated genomewide transcriptional response to administration of either BTS or BOT to the Korean obese adults. From the blood samples, peripheral blood mononuclear cells (PBMCs) were isolated and RNA samples extracted from PBMCs were processed to conduct DNA microarray. Analysis of DNA microarray data revealed that administration of the both BTS and BOT evokes gene expression profile changes of PBMCs. In addition, comparative analysis between the drugs and placebo identified sets of specific genes regulated by BTS or BOT. Interestingly, analysis of gene list using functional annotation tool revealed that PMBCs of BOT-prescribed subjects have increased expression level of genes which are localized to mitochondria. The fact that mitochondrion is the main organelle of regulating cellular energy metabolism suggests that induced expressions of mitochondrial genes by BOT administration might be responsible for the anti-obesity effect of the medicine. We expect that further study based on our finding will provide molecular mechanisms of BTS and BOT effects on obesity.